We recently described a non-viral gene therapy paradigm offering long-term resolution of established neuropathic pain in several animal models. Here, the requirements for longterm therapeutic effects are described, and evidence is provided for a mechanism of action based on immunological priming of the intrathecal (i.t.) space. Long-term pain reversal was achieved when two i.t. injections of various naked plasmid DNA doses were separated by 5 h to 3 days. We show that an initial DNA injection, regardless of whether a transgene is included, leads to an accumulation of phagocytic innate immune cells. This accumulation coincides with the time in which subsequent DNA injection efficacy is potentiated. We show the ability of non-coding DNA to induce short-term pain reversal that is dependent on endogenous interleukin-10 (IL-10) signaling. Long-term efficacy requires the inclusion of an IL-10 F129S transgene in the second injection. Blockade of IL-10, by a neutralizing antibody, either between the two injections or after the second injection induces therapeutic failure. These results show that this gene therapy paradigm uses an initial 'priming' injection of DNA to induce accumulation of phagocytic immune cells, allowing for potentiated efficacy of a subsequent 'therapeutic' DNA injection in a time-and dosedependent manner.
Introduction
Gene therapy is the delivery of nucleic acids (DNA or RNA) into host cells by viral or non-viral means to achieve chronic production or suppression of a protein with therapeutic significance. The main advantage of gene therapy lies in the potential for long-term expression of a therapeutic protein or in long-term suppression of a deleterious protein. The potential for long-term efficacy is particularly important when treating a variety of chronic diseases.
Two major obstacles prevent the widespread use of gene therapy in the clinic. The first obstacle lies in the difficulty of delivering genes into host cells. 1, 2 The second obstacle lies in maintaining long-term efficacy, often owing to a host immune response against either the therapeutic gene product or the delivery vector. [3] [4] [5] [6] The immune response can suppress gene expression as well as prevent successful vector reintroduction. Viral vectors are highly efficient at gene delivery, although these vectors tend to provoke an immune response that can terminate the therapy and can pose potential serious health risks to patients. Non-viral vectors are far less efficient at gene delivery, although they tend to be less immunogenic and, therefore, can lead to longterm gene expression, albeit at low levels. Thus, immunogenicity is generally viewed as a significant hindrance to the development of clinically viable gene therapies.
However, immunogenicity may powerfully benefit gene therapy when carefully used. We have developed a novel, two-injection non-viral gene therapy paradigm using naked plasmid DNA that suggests vector immunogenicity can be exploited to potentiate therapeutic efficacy.
The gene therapy described here makes use of naked plasmid DNA coding for a single amino acid variant of the anti-inflammatory cytokine interleukin-10 (IL-10 F129S ; see Materials and methods) to treat a model of neuropathic pain after peripheral nerve injury. Inflammation in the central nervous system is a well-documented phenomenon that occurs after a wide variety of insults including peripheral nerve injury. [7] [8] [9] [10] Neuropathic pain is one common symptom of central nervous system inflammation that has proven particularly difficult to treat in the clinic. 11 A large body of evidence suggests that symptoms of inflammatory neuropathies, including chronic pain, may be controlled by targeting the activation of resident immune cells within the central nervous system (glia). [12] [13] [14] [15] [16] IL-10 has the well-documented ability to suppress glial activation and the production of inflammatory mediators that contribute to the expression of pain. [17] [18] [19] [20] Intrathecal (i.t.) administration of either IL-10 protein or IL-10 viral vectors is able to reverse neuropathic pain. 21, 22 Consistent with a short half-life, the therapeutic effects of IL-10 protein for pain reversal normally lasts only a few hours, whereas viral vector IL-10 leads to pain reversal lasting a few weeks. Using a two successive injection approach, as will be described, reversal of pain can be achieved for a strikingly longer period of time, at least 3 months. The reversal of peripheral nerve injury-induced pain is used as the primary measure of therapeutic efficacy in these studies.
Taken together, the data presented here are suggestive of a local innate immune response that is provoked by an i.t. plasmid DNA injection and leads to the accumulation of activated immune cells, which in turn allows for dramatically enhanced efficacy of a subsequent plasmid DNA treatment. This approach has potential applicability in a variety of other gene therapy contexts and may serve as a useful model in the development of clinically viable therapies.
Results
Long-term reversal of pain after two i.t. pDNA-IL-10 F129S injections Initial work in our lab using i.t. non-viral gene therapy for pain control showed increasing efficacy of 100 mg i.t. pDNA-IL-10 F129S on repeated injections such that the duration of pain suppression increased with each subsequent pDNA-IL-10 F129S administration. 23 When the time between two injections was shortened from 5 days to either 2 or 3 days, pain reversal was extended from less than a week (5 day interval) to over a month (2-3 day intervals). We now report a further extension of pain reversal to at least 3 months that is achieved by decreasing the dose of pDNA-IL-10 F129S from 100 to 25 mg on the second i.t. injection (Figure 1 ). Although it is not certain why a lower dose of pDNA-IL-10 F129S on a second injection should increase the therapeutic duration, we speculate that 100 mg of DNA on a second injection may induce a strong inflammatory response that ultimately shortens the duration of the therapy. The role of inflammatory signaling in both the induction and stability of this gene therapy will be described and discussed below.
A minimum time delay between successive injections and innate immune cell accumulation is required for long-term therapeutic effect
Given the dramatically extended therapeutic duration observed by decreasing the amount of time between injections, short inter-injection intervals were examined as well as i.t. events in the hours after a pDNA injection. Figure 2a shows that a minimum inter-injection interval of approximately 5 h is required to achieve long-term pain reversal. Separating the pDNA injections by 2 h or administration of an equal total amount of pDNA-IL-10 F129S (125 mg) as a single bolus, leads to pain reversal equivalent to a single 100-mg pDNA-IL-10 F129S injection. Although shorter inter-injection intervals (0-2 h) lead to the same magnitude of pain reversal as do longer interinjection intervals (5 days), the duration of pain reversal after a 0-2 h inter-injection interval is approximately 7-10 days compared with a 5 h inter-injection interval, which produces pain reversal maintained for at least 90 days. Figure 2b shows the time course of cellular accumulation in lumbosacral cerebrospinal fluid (CSF) in the hours and days after lumbosacral i.t. injection. A significant increase in CSF cell count is observed at 6 h post DNA injection, approximately the same time as the earliest inter-injection interval that leads to long-term pain reversal. Cell counts in CSF peak at 24 h and return to near baseline levels at 6 days, corresponding to the window of time in which the efficacy of a second DNA injection is potentiated. The accumulation of cells within CSF occurs only after pDNA injection and not after equivolume vehicle injection. Figure 2c displays the cell phenotypes in CSF after DNA injection. At 6 h after injection, a shift towards CD63+ cells (undifferentiated monocytes and mast cells) is observed. At all other time points, the overwhelming majority of cells were identified as macrophages (classically activated ED1+ or alternatively activated ED2+). Figure 3 includes representative photos of cells collected from lumbar CSF 24 h 
Figure 1
Long-term reversal of peripheral nerve injury-induced neuropathic pain. Baseline (BL) responsivity to calibrated lowthreshold mechanical stimuli (von Frey test) was recorded before either chronic constriction injury (CCI; black squares) of the left sciatic nerve or sham operation (red diamonds). Von Frey testing reoccurred through 90 days after surgery at time points indicated on the X-axis. Ten days after surgery, a time by which robust mechanical allodynia had developed, rats received an initial intrathecal injection of 100-mg pDNA-IL-10 F129S (see first arrow along the X-axis). This was followed 3 days later by a 25-mg pDNA-IL-10 F129S injection (see second arrow along the X-axis). This injection schedule led to at least 3 months of reversal of neuropathic pain. The left hand Y-axis represents 50% withdrawal threshold (that is, absolute threshold) on the von Frey logarithmic scale. The right hand Y-axis represents the 50% withdrawal threshold in gram force. Significant reversal of CCI-induced allodynia observed on Day 10 rapidly developed within 24 h after first injection, and lasted the duration of the experiment (Po0.01). The CCI-operated and sham-operated groups each include six rats across two replications. Error bars indicate s.e.m.
Harnessing innate immunity to enhance gene therapy E Sloane et al after a 100-mg pDNA-control ( Figure 3a ) or vehicle ( Figure 3b ) injection and plated for immunofluorescence analysis. Evidence that cell accumulation involves an inflammatory response to the pDNA injection is provided in Figure 3c . Intrathecal injections of anti-inflammatory IL-10 protein given 4 h before and co-injected along with an i.t. 100-mg pDNA injection prevents the accumulation of cells in CSF ( Figure 3c ) and prevents the long-term reversal of pain normally observed after pDNA-IL-10 F129S injections (Figure 3d ).
The immune response in CSF to DNA: cell influx and IL-10 induction A large range of pDNA-IL-10 F129S doses given as a second DNA injection produce long-term reversal of pain ( Figure 4 ). 23 Although the magnitude of pain reversal is equivalent between second injection doses ranging from 100 to 1 mg, the duration of pain reversal varies depending on dose. Two injections of 100-mg pDNA-IL-F129S lead to pain reversal lasting approximately 30-40 days, 23 whereas a 25 g second injection reverses pain for at least 3 months and a 1 mg second injection reverses pain for 82 days.
During the course of these experiments, we made the surprising observation that an i.t. injection of pDNA that does not code for a gene (pDNA-control), led to shortterm reversal of pain. Reversal of pain 48 h after injection of either pDNA-control or pDNA-IL-10 F129S is dependent on IL-10 signaling (Figure 5a ). PCR analysis of plasmidderived IL-10 gene expression within CSF samples collected 48 h after a single pDNA-IL-10 F129S injection 
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6D 3D 24H 6H Figure 2 Behavioral and intrathecal cellular events after a 100-mg DNA injection. (a) A minimum of 5 h lapse between successive pDNA-IL-10 F129S injections is required to achieve long-term efficacy in reversing neuropathic pain. Baseline (BL) responsivity to calibrated lowthreshold mechanical stimuli (von Frey test) was recorded before chronic constriction injury (CCI) of the left sciatic nerve or sham operation. Von Frey testing re-occurred through 68 days after surgery at time points indicated on the X-axis. Ten days after surgery, a time by which robust mechanical allodynia had developed, rats received either one (125 mg) or two (100 mg followed 2 or 5 h later by 25 mg) intrathecal injections of pDNA-IL-10 F129S totaling 125 mg for each group. The point in time in which these injections occurred is indicated by an arrow along the X-axis; a single arrow is shown given how compressed in time the two injections occur relative to the timescale of the X-axis. Longterm therapeutic efficacy is not achieved if pDNA-IL-10 F129S is given as a single 125 mg dose (black squares) or if a 25 mg second pDNA-IL-10 F129S injection occurs 2 h after an initial 100-mg pDNA-IL-10 F129S injection (red diamonds). The reversal of allodynia as compared with preinjection levels was observed until day 10 after pDNA-IL-10 F129S injections for the 125 mg single injection as well as for the 2 h interval (Po0.01). In contrast, 5 h interval between the 100 and 25 mg injections, was sufficient to reverse allodynia (green circles) throughout the duration of the experiment (58 days), as compared with pre-injection withdrawal thresholds recorded on days 3 and 10 post-CCI surgery (Po0.01). This same 5-h dosing regimen delivered to sham-operated controls (blue triangles) had no effect on responsivity to the von Frey test. Error bars indicate s.e.m. (b) Cell influx into cerebrospinal fluid (CSF) occurs after intrathecal pDNA injection. Cell counts (Y-axis label) in lumbar CSF per Â 20 magnification view field are displayed. Significant increases in cell counts compared with pre-injection are observed from 6 h to 3 days after pDNA (white bars), but not vehicle (black bars) or no (diagonal stripes), injection. This 6 h to 3-day temporal window corresponds to the time during which the efficacy of a second DNA injection for reversing neuropathic pain is potentiated (see panel a of this figure) . Error bars indicate s.e.m. (c) Cell phenotype percentages are displayed as percentage of total cells (Y-axis labels) positively staining with ED1 (red bars), ED2 (blue bars), CD63 (green bars) or unlabeled (white bars) after vehicle pDNA-IL-10 F129S injection. At the time of initial DNA injection (pre-injection; left-most bar), the local population of innate immune cells is relatively small. By 6 h post DNA injection (6 h time after injection; third bar), a dramatic shift in the number and activation state of immune cells is observed as compared with pre-injection cell counts (Po0.01). This same pattern of cell influx was observed after injection of pDNA without transgene (pDNA-control), pDNA coding for green fluorescent protein (GFP) as well as after a bicistronic plasmid construct containing IL-10 and GFP (data not shown). All time points reflect data collected from four animals per group. Error bars indicate s.e.m.
Harnessing innate immunity to enhance gene therapy E Sloane et al shows significant gene expression as compared with a pDNA-control injection ( Figure 5b ). There was no difference at this time point in endogenous IL-10 gene expression in CSF, supporting the notion that the DNA injection itself leads to a temporary endogenous elevation of IL-10 protein (data not shown). Continuous IL-10 signaling is required between the two pDNA injections for long-term pain reversal, as injection of IL-10neutralizing antibody, but not control IgG, 24 h (or 48 h; data not shown) after the first pDNA-IL-10 F129S injection caused an initial re-expression of pain behavior as well as the failure of the therapy after a properly timed second pDNA-IL-10 F129S injection ( Figure 5c ).
Characterization of i.t. sensitization after pDNA injection
Injection of 100 mg of pDNA-control as an initial priming injection followed by 25-mg pDNA-IL-10 F129S leads to the same reversal of pain as two injections of pDNA-IL-10 F129S (Figure 6a ). Importantly, injection of pDNA-IL-10 F129S as the first injection followed by pDNA-control on the second DNA injection fails to lead to long-term pain reversal ( Figure 6b ). Intrathecal sensitization is also observed after injection of stimulatory synthetic oligodeoxynucleotides, agonists of the innate immune receptor Toll-like receptor 9 (TLR 9), in a dose-dependent manner (Supplementary Figure S1 ). Disruption of IL-10 signaling by i.t. injection of IL-10-neutralizing antibody (anti-IL-10) after the second pDNA injection leads to a rapid and sustained re-expression of pain behavior ( Figure 7a ). This induced failure of the therapy is remarkably persistent, lasting the duration of the experiment (30 days after neutralizing antibody administration). The persistent re-expression of neuropathic pain is not owing to a lingering inability to respond to IL-10 protein, as injection of IL-10 protein at either 4 days (Supplementary Figure S2 ) or 3 weeks (data not shown) after injection of anti-IL-10 is still highly effective at reversing pain. The strikingly long therapeutic duration of IL-10 protein observed here is addressed in the discussion below. Interestingly, the destabilizing effect of anti-IL-10 can be mimicked by i.t. injection of the proinflammatory HIV coat protein, gp120 (Glycoprotein120), at a dose that is sufficient to cause the temporary expression of enhanced pain in naïve animals (Supplementary Figure S3 ). Polymerase chain reaction analysis for plasmidderived IL-10 gene expression in CSF samples was conducted either before or after either neutralizing anti-IL10 or control antibody injection ( Figure 7b ). CSF samples collected 22 days after two successive pDNA-IL- Harnessing innate immunity to enhance gene therapy E Sloane et al 10 F129S injections (100 mg followed by 25 mg), but not two successive pDNA-control injections (100 mg followed by 25 mg), showed significant plasmid-derived gene expression. Additional groups received i.t. injection of either anti-IL-10-neutralizing antibody or control IgG antibody on day 22 after the second of two successive i.t. injections of pDNA-IL-10 F129S (100 mg followed by 25 mg); CSF samples were collected 4 days later. PCR analysis of these CSF samples showed equivalent plasmid-derived IL-10 gene expression after control IgG antibody injection as compared with 22 days after pDNA-IL-10 F129S injection. Anti-IL-10 antibody injection, however, reduced plasmid-derived IL-10 gene expression in CSF to background levels (equivalent to pDNA-control) ( Figure 7b ).
After the eventual re-expression of neuropathic pain behavior, a single pDNA-IL-10 F129S injection re-instates long-term reversal of pain if delivered within days An initial priming injection of 100-mg pDNA-IL-10 F129S followed 3 days later by 25-mg pDNA-IL-10 F129S leads to reversal of pain that outlasts the durability of the neuropathic pain model being tested. If, however, two successive 25 mg doses of DNA are administered, reversal of pain lasts for only 1 month (Figures 8a  and b ). Figure 8a shows the ability of a single 25-mg pDNA-IL-10 F129S injection to lead to at least 2 months of full pain reversal if delivered 4 days after the failure of the first two injections. If, instead, the third 25 mg injection is administered 3 weeks after the failure of the initial two injections, a partial reversal of pain is noted only at 24 h after the third injection ( Figure 8b ).
Discussion
We here describe a non-viral gene therapy paradigm in which an IL-10 transgene containing a point mutation (pDNA-IL-10 F129S ) is injected into the i.t. space around the spinal cord to treat a model of neuropathic pain. This point mutation retains in vivo anti-inflammatory activity, as has been documented in several independent labs in models of chronic renal disease, 24 aortic tissue transplantation, 25 spinal nerve transaction, 26 experimental autoimmune encephalomyelitis 27 and sciatic nerve ligation. 22 Long-term efficacy of this therapy requires a pDNA-IL-10 F129S injection anytime from 5 h to 3 days after an initial i.t. injection of DNA. The initial DNA injection provokes the accumulation of phagocytic innate immune cells and the production of endogenous IL-10 whether or not a transgene is present in the plasmid vector. Long-term therapeutic stability requires an initial immune cell accumulation as well as continuous IL-10 signaling beginning at 24 h after the first DNA injection. Upon failure of the therapy (measured by re-expression of pain behavior), a single injection of pDNA-IL-10 F129S is able to re-instate long-term pain relief if delivered within days of therapy failure.
The work presented here describes the timing and dose requirements of a non-viral gene therapy method by which long-term suppression of neuropathic pain is achieved. The model of neuropathic pain used here to characterize therapeutic efficacy has been widely used to determine the mechanistic basis for the expression of neuropathic pain as well as to test potential therapeutics. [28] [29] [30] [31] This paper does not focus on the mechanistic basis of neuropathic pain expression and the readers are referred to several articles on the contributions of cytokines to neuropathic pain and the therapeutic use of regulatory cytokines such as IL-10. 22, [32] [33] [34] [35] A behavioral end point (von Frey test of allodynia) is used as the primary measure of therapeutic efficacy for several reasons. First, there is convincing pharmacological evidence indicating the crucial role of proinflammatory cytokines in the expression of neuropathic pain. 12 For example, IL-1 receptor antagonist or IL-10 protein are both able to reverse neuropathic pain in this model of neuropathy. 36 As proinflammatory cytokines have rare and unstable mRNAs, 37 and, as a result of which only few molecules need be released to exert biological actions, behavioral end points rather than protein or Here, baseline (BL) responsivity to calibrated low-threshold mechanical stimuli (von Frey test) was recorded before chronic constriction injury of the left sciatic nerve or sham operation. Von Frey testing re-occurred through 82 days after surgery at time points indicated on the X-axis. Ten days after surgery, a time by which robust mechanical allodynia had developed, rats (N ¼ 6 per group across two replications) received an initial 100-mg pDNA-IL-10 F129S dose (at first arrow along X-axis) followed by either 25-mg (black square) or 1-mg (red diamond) pDNA-IL-10 F129S or vehicle (green circle) injection 3 days later (at second arrow along X-axis); alternatively, a non-coding pDNA-control was administered (at first arrow) followed 3 days later by non-coding pDNA-control (blue triangles) (at second arrow). Reversal of allodynia, as compared with pre-injection withdrawal thresholds at days 3 and 10 post-surgery, was observed for the duration of the experiment in rats receiving an initial 100-mg pDNA-IL-10 F129S dose followed by a second injection dose of 25 mg (Po0.01; black squares) until day 82 after a second injection dose of 1 mg (Po0.01; red diamonds) and until day 2 after vehicle injection (Po0.01; green circles). Significant reversal of allodynia as compared with pre-injection withdrawal thresholds was noted after a 100-mg pDNA-control injection followed 3 days later by 25-mg pDNA-control (blue triangle symbol), starting 24 h after the first injection and lasting until day 4 after the second injection (Po0.01; N ¼ 6). Error bars indicate s.e.m.
Harnessing innate immunity to enhance gene therapy E Sloane et al mRNA have proven to be the most sensitive assay. We show that long-term reversal of pain observed in this paradigm is dependent on the inclusion of an IL-10 transgene on the second injection. Pain reversal as well as plasmid-derived gene expression after the second injection is mediated by IL-10 protein, as shown by the re-expression of pain and a loss of gene expression after injection of IL-10-neutralizing antibody. The current studies indicate a requirement of innate immune cell influx before the 'therapeutic' injection in order to achieve long-term efficacy. Further study is necessary to determine whether this influx facilitates gene uptake, subsequent gene expression, prevention of gene silencing, transfection of alternative cell types or induction of specific immune cell phenotypes that perhaps exert bystander therapeutic benefits. The results of the present series of studies will form the basis for such mechanistic analyses, now that the fundamental characterization of the phenomenon has been clarified.
Gene therapy vectors are inherently immunogenic
Elaborate and powerful immunological mechanisms exist in an organism to prevent and contain infections. These mechanisms can result in recognition and destruction of therapeutic viral vectors, destruction of infected host cells or in silencing of therapeutic gene expression. 3 Gene therapy by design introduces exogenous RNA or DNA into host cells. It is not surprising then, that immunogenicity has been viewed as a major hurdle in the generation of viable gene therapy applications. 2 Immune responses broadly fall into two categories, innate immunity and adaptive immunity. The innate immune response occurs locally at the site of infection, whereas an adaptive response is systemic and involves the generation of highly antigen-specific effector cells (T cells and B cells). The innate response begins with the rapid production of a wide variety of cytokines and chemokines, which occurs in the first few hours after detection of a 'danger signal', 38, 39 and promotes immune (c) Long-term efficacy of gene therapy is blocked by temporary blockade of IL-10 signaling. Long-term therapeutic efficacy requires IL-10 signaling between the two DNA injections. Here, baseline (BL) responsivity to calibrated low-threshold mechanical stimuli (von Frey test) was recorded before chronic constriction injury of the left sciatic nerve. Von Frey testing re-occurred through 30 days after surgery at time points indicated on the X-axis. Ten days after surgery, a time by which robust mechanical allodynia had developed, all rats received intrathecal administration of 100-mg pDNA-IL-10 F129S (at first black arrow along X-axis). A single administration of IL-10-neutralizing antibody (black squares), but not control IgG (red diamonds), 24 h after pDNA-IL-10 F129S injection (at green arrow along X-axis) acutely blocks (4 h (Hr4)) short-term reversal of neuropathic pain as well as chronically blocks the sustained reversal of neuropathic pain induced by a second pDNA-IL-10 F129S injection (N ¼ 6 per group across two replications). Re-expression of allodynia as compared with pre-injection withdrawal thresholds (days 3 and 10 post-surgery) was noted in IL-10-neutralizing antibody-injected rats by day 2 after the second pDNA injection. Error bars indicate s.e.m.
Harnessing innate immunity to enhance gene therapy E Sloane et al cell extravasation from circulation. The early response involves clearing of cellular debris and potential infectious agents by highly phagocytic cells recruited to the area, which can be observed after approximately 4 h. 40 The innate immune response typically resolves 4 days after initiation, when adaptive immunity becomes more prominent. The events occurring during an innate Here, baseline (BL) responsivity to calibrated low-threshold mechanical stimuli (von Frey test) was recorded before chronic constriction injury of the left sciatic nerve. Von Frey testing reoccurred through 90 days after surgery at time points indicated on the X-axis. Ten days after surgery, a time by which robust mechanical allodynia had developed, one group of rats received an injection of 100-mg pDNA-control (at red arrow along X-axis) followed 3 days later by 25-mg pDNA-IL-10 F129S (at black arrow along X-axis). Reversal of allodynia as compared with pre-injection withdrawal thresholds was noted 24 h after pDNA-control injection and lasted the duration of the experiment (Po0.01; N ¼ 6). Error bars indicate s.e.m. (b) pDNA-IL-10 F129S efficacy is not potentiated by a subsequent pDNA-control injection. The first injection stimulus enhances only a subsequent injection. Rats were prepared and behaviorally tested as in panel a. Ten days after surgery, rats received 100-mg pDNA-IL-10 F129S intrathecally (at black arrow along X-axis) followed 3 days later by 25 mg of non-coding pDNA-control (at red arrow along X-axis). Given the failure to attain long-duration reversal of neuropathic pain, these data indicate that in order to achieve long-term pain reversal, the second DNA injection must include the IL-10 gene. Efficacy of an initial 100-mg pDNA-IL-10 F129S injection cannot be enhanced by a subsequent 25-mg pDNA-control injection. Allodynia is reversed until day 2 after second injection as compared with pre-injection withdrawal thresholds. Figure 7 Therapeutic stability and plasmid-derived gene expression require continuous IL-10 signaling. (a) Long-term gene therapy stability requires IL-10 signaling. Long-term therapeutic efficacy requires continuous IL-10 protein signaling after the second pDNA-IL-10 F129S injection. Here, baseline (BL) responsivity to calibrated low-threshold mechanical stimuli (von Frey test) was recorded before chronic constriction injury of the left sciatic nerve. Von Frey testing re-occurred through 30 days after surgery at time points indicated on the X-axis. Ten days after surgery, a time by which robust mechanical allodynia had developed, rats received 100-mg pDNA-IL-10 F129S followed 3 days later by 25-mg pDNA-IL-10 F129S (at time points indicated by two serial black arrows on X-axis). A single injection (at green arrow on X-axis) of IL-10-neutralizing antibody (0.2 mg; red diamonds; N ¼ 6, across two replications) led to the rapid and sustained re-expression of pain behavior as compared with pre-injection withdrawal thresholds (Po0.01 beginning at 2 h after injection of neutralizing antibody and lasting the remainder of the experiment). Control IgG injection (at green arrow on X-axis) did not disrupt long-term therapeutic efficacy (black squares; N ¼ 6, across two replications). Error bars indicate s.e.m. (b) Plasmid-derived gene expression requires continuous IL-10 signaling. Rats were prepared as in panel a. At 22 days after the second pDNA-IL-10 F129S injection (100 mg followed by 25 mg), significant plasmid-derived IL-10 expression is observed in cells contained in the lumbosacral cerebrospinal fluid (CSF) (second bar), compared with rats receiving two successive intrathecal injections (100 mg followed by 25 mg) of non-coding pDNA-control (first bar) (Po0.05). The remaining rightward two bars represent data of separate groups of rats that had also received two successive intrathecal injections of (100 mg followed by 25 mg) pDNA-IL-10 F129S before challenge by intrathecal antibody. A single injection of IL-10-neutralizing antibody (0.2 mg; N ¼ 6, across two replications) given on day 22 post second pDNA-IL-10 F129S injection (third bar) reduced plasmid-derived IL-10 gene expression in lumbosacral CSF to background levels (equivalent to levels after pDNA-control injections) within 4 days (the time point of CSF analysis shown here). Injection of an equivalent amount of control IgG antibody (N ¼ 6, across 2 replications) given under the same conditions has no effect on exogenous IL-10 gene expression in CSF as compared with the levels observed at day 22 post second pDNA-IL-10 F129S injection (rightmost bar).
Harnessing innate immunity to enhance gene therapy E Sloane et al immune response (phagocytic cell influx from approximately 4 h to 4 days) show strong parallels to the events after the initial DNA injection in the current gene therapy paradigm (phagocytic cell accumulation and sensitized response to a subsequent plasmid DNA injection from approximately 5 h to 3 days) and will be discussed below.
DNA-based vectors trigger an innate immune response
A family of receptors known as the TLRs is found on many immune cells important for the innate immune response, including macrophages and mast cells. This family of receptors consists of more than 10 different receptor types, each of which differentially recognizes antigens that are associated with particular pathogens. 41 TLR activation is a key event in immune response initiation, and the downstream signaling of particular TLRs can have a profound impact on the phenotypes of cells that are ultimately localized to the site of infection. 42 Of particular relevance to gene therapy applications are the TLRs that are able to recognize RNA (TLR 3 and 7) or specific unmethylated DNA sequences known as CpG motifs (TLR 9) that are common to bacteria and viruses, as well as to plasmid gene therapy vectors. TLR 9 stimulation in monocytic cell lines (which give rise to macrophages and mast cells) leads to the production of a panel of cytokines and chemokines that direct cell recruitment and differentiation into particular phenotypes. 43 Cytokines are roughly categorized as either Th1 (T helper 1) or Th2 (T helper 2) types, which are produced by, and direct the generation of, either Th1 or Th2 T-cell subsets. 40 TLR 9 activation in monocytes eventually results in a Th2-biased response, including the production of IL-10, with little production of classic Th1 inflammatory mediators. 43, 44 The gene therapy employed in the current studies is delivered i.t. into the CSF, percolating through the fibrous network of cells that make up the meninges and surround the spinal cord. A large number of innate immune cells reside in the meninges, including mast cells and macrophages (meningeal and perivascular macrophages). 45, 46 These immune cells residing i.t. express TLR 9 and tend to respond to immune challenges by production of Th2 cytokines, including the interleukins IL-4 and IL-10. 47 It is shown here that reversal of peripheral injury-induced pain occurs in an IL-10-dependent manner by 48 h after a single i.t. DNA injection, regardless of the gene being delivered. Thus, it seems that resident innate immune cells within the meninges respond to DNA administration by producing Th2 cytokines, including IL-10.
In addition to cytokine production, resident monocytic cells may produce a wide variety of chemokines after DNA administration that may induce cell extravasation from circulation. These chemokines include monocyte chemoattractant protein 1 and monocyte inflammatory protein 1 beta, both of which potently recruit undifferentiated monocytes. CD63 is a lysosomal protein expressed by undifferentiated monocytes. 40 Monocytes differentiate into a mature phenotype once they are recruited from circulation into tissue after an immune challenge. It is likely that a significant proportion of the CD63+ cells observed in CSF 6 h after an i.t. DNA injection are newly recruited monocytes that have not yet differentiated, and ultimately give rise to the macrophage population observed in CSF at later time points. IL-10 has the well-documented ability to block the activation and production of multiple inflammatory cytokines and chemokines by a variety of immune cells, including macrophages and mast cells. 48, 49 We show here that i.t. pretreatment and co-injection of recombinant IL-10 protein along with a DNA injection, designed to block inflammatory signaling that leads to immune cell influx, in fact does prevent the accumulation of cells into CSF at the site of injection as well as block the long-term efficacy of a subsequent pDNA-IL-10 F129S injection. This strongly suggests an initial inflammatory response to the DNA injection, with likely production of chemotactic factors, responsible for the extravasation of phagocytic immune cells. A required minimum inter-injection interval provides additional support for the crucial role played by cell accumulation in CSF. BL 3  1  10  48  40  24  10  6  4  2  34  26  18  10  6  4  2  1  3  2   BL 3  1  1  34  26  18  10  6  4  2  1  3  2  10 42 50 30 22 14 10 6 4 2 Figure 8 Time-dependent reinstatement of long-term gene therapy efficacy. For both panels, baseline (BL) responsivity to calibrated low-threshold mechanical stimuli (von Frey test) was recorded before chronic constriction injury of the left sciatic nerve. Von Frey testing re-occurred after surgery at time points indicated on the Xaxis. Ten days after surgery, a time by which robust mechanical allodynia had developed, rats received two successive intrathecal injections of pDNA-IL-10 F129S (at black arrows along X-axis). (a) Sensitization of the intrathecal space to a pDNA-IL-10 F129S injection is time dependent after failure of the therapy. A priming dose of 25-mg pDNA-IL-10 F129S followed 3 days later by a second 25mg pDNA-IL-10 F129S dose leads to reversal of pain for approximately 1 month (Po0.01; N ¼ 6, as 2 replications) as compared with preinjection withdrawal thresholds. Here, a third 25-mg pDNA-IL-10 F129S injection was administered within 4 days of the re-expression of pain, reinstating a long-term therapeutic effect (42 month effect, Po0.01; N ¼ 6, as two replications). Error bars indicate s.e.m. (b) Here, the same 25-mg pDNA-IL-10 F129S dose was administered approximately 3 weeks after re-expression of allodynia, leading to a small and variable therapeutic effect (peak therapeutic effect on day 4). Error bars indicate s.e.m.
Harnessing innate immunity to enhance gene therapy E Sloane et al
Provoked accumulation of phagocytic cells into CSF facilitates enhanced gene delivery
Cells present in CSF at 24 h are primarily macrophages that strongly express ED1, a marker of classic macrophage activation. Over the course of the following several days, a phenotype shift occurs with a larger percentage of macrophages expressing ED2 (also known as CD163), a marker of alternative activation associated with the resolution of an immune response. 50, 51 Macrophages are best known for their role in the clearance of cellular debris through their highly phagocytic activity. An increase in the population of these cells would likely increase the chances of DNA uptake after injection. The ability of a very-low-dose second injection of pDNA-IL-10 to provide long-term reversal of pain behavior provides supporting evidence for increased gene uptake during the period of i.t. cell accumulation. The focus of these studies is on the i.t. response to DNA. It remains to be determined to what extent the immune response that enhances subsequent DNA injections is specific to DNA.
IL-10 protein stabilizes long-term gene therapy efficacy and plasmid-derived gene expression
Continuous IL-10 signaling seems to be required for long-term reversal of pain beginning at 24 h after the first DNA injection and lasting through the duration of the therapy. Although the actions of IL-10 protein that provide long-term therapeutic stability are unknown, it is possible that IL-10, through its anti-inflammatory activity, prevents the activation of immune cells that would otherwise lead to a migration of those accumulated immune cells away from the i.t. space and to draining lymph nodes. 40 There also seems to be a positive feedback loop between IL-10 signaling and ongoing plasmid-derived gene expression, as blockade of total IL-10 protein leads to a suppression of exogenous IL-10 gene expression, perhaps by transgene silencing. The surprising observation that a single injection of IL-10 protein, which normally leads to pain reversal lasting several hours, is able to lead to pain reversal lasting upwards of 30 days when administered after the induced failure of this gene therapy may lend credence to the notion of a positive feedback loop encouraging gene expression, perhaps by unmasking transgene expression and protecting it from further silencing by inducing the ongoing release of IL-10. Alternatively, it may be the case that local immune cell populations have become predisposed to the endogenous production of anti-inflammatory factors, as is the case with alternatively activated macrophages, which can be induced after prolonged exposure to IL-10 protein. Future studies are required to explore this question adequately. Plasmid-derived IL-10 may contribute to a Th2-dominant cytokine profile that is permissive of continued plasmid gene expression. The fact that injection of the inflammatory protein, gp120, a strong inducer of Th1 cytokines, 52 mimics the long-term destabilization of the gene therapy seen after administration of IL-10-neutralizing antibody suggests that the cytokine milieu is the key factor in stabilizing the gene therapy and not an effect specific to IL-10 receptor activity. The ability of a single pDNA-IL-10 F129S injection to reinstate long-term pain reversal if administered 4 days, but not 3 weeks, after a failure of gene therapy (re-expression of pain behavior) is strongly indicative of a parallel between the period of behavioral reversal (and Th2 dominant cytokine milieu) and the period of sensitization to DNA injection.
Harnessing innate immunity to enhance gene therapy is a model with potential widespread applicability
The paradigm presented here describes the effect of a 'priming' i.t. DNA injection followed by a 'therapeutic' DNA injection. The priming injection serves the purpose of recruiting phagocytic cells from circulation to enhance uptake of gene therapy vector. The therapeutic injection contains the gene(s) of interest and is delivered into an environment that dramatically improves its efficacy. Further study is necessary to determine whether this approach will enhance other gene delivery applications, or whether the inclusion of Th2 type genes along with a desired therapeutic gene will broadly and consistently increase the therapeutic stability and duration. 
Materials and methods
Surgery
Chronic constriction injury was created at mid-thigh level of the left hind leg, as previously described. 53 Briefly, under isoflurane anesthesia (Phonex Pharm, St Joseph, MO, USA) the left sciatic nerve was exposed by blunt dissection of the overlying muscle and gently isolated with glass surgical tools. Four chromic gut sutures (cuticular 4-0, cutting FS-2; Ethicon, Somerville, NJ, USA) were then tied loosely around the nerve. Shamoperated animals had the sciatic nerve identically isolated but not ligated. The muscle was then sutured with silk suture (4.0, Ethicon) and the skin incision closed with wound clips. Animals were allowed to recover and were monitored daily for overall health.
von Frey test
The von Frey test was performed on the hind paws, as previously described in detail. 22, 27 Briefly, a logarithmic series of 10 calibrated Semmes-Weinstein monofilaments (von Frey hairs: Stoelting, Wood Dale, IL, USA) was applied randomly to the left and right hind paws to determine the stimulus intensity threshold stiffness required to elicit a paw withdrawal response. Log stiffness of the hairs is determined by log 10 (milligrams Â 10). The range of monofilaments used in these experiments (0.407-15.136 g) produces a logarithmically graded slope. Data are presented as interpolated 50% response threshold to stimulus intensity in log 10 (milligrams Â 10). Behavioral measures were recorded before surgery, at days 3 and 10 after surgery and every few days after injections for the remainder of 
Intrathecal injections
Injections were acutely administered i.t., as previously described. 21 Briefly, animals were anesthetized with isoflurane, and an 18-G hypodermic needle (Beckton Dickinson & CO, Franklin Lakes, NJ, USA) was removed from its hub and percutaneously inserted between lumbar (L) vertebrae L5 and L6. A catheter of PE-10 tubing (Beckton Dickinson & CO, Sparks, MD, USA) was then threaded through this 18-G guide 7.7-cm rostrally, allowing for the tip of the catheter to be placed at the level of the lumbosacral enlargement. Injections were administered over approximately 10-20 s. The PE-10 catheter and 18-G needle were then removed and anesthesia discontinued. Animals were anesthetized for an average of 3-5 min during injection and no abnormal behavior was noted upon recovery from anesthesia.
Naked plasmid DNA
All plasmid DNA injections were delivered at a concentration of 5-6 mg ml À1 . The plasmid construct coding for rat IL-10 (pDNA-IL-10 F129S ) was identical to that previously described. 23 Briefly, this plasmid contains cDNA encoding rat IL-10 under the control of a hybrid cytomegalovirus enhancer/chicken beta actin promoter. A point mutation resulting in an amino acid change (F129S) has been identified in the rat IL-10 gene expressed in these studies. This mutation lies outside of identified receptor-binding regions. The effect of this point mutation on IL-10 bioactivity in vitro is currently under investigation. Preliminary results with macrophages and B cells suggest differences between wild type and variant (Busha and Chavez, personal communications). However, this construct has previously been documented to exert anti-inflammatory activity in vivo across diverse models of inflammation. Plasmid was grown up in SUREII cells (Stratagene, CA, USA; catalog no. 200152). Isolation and purification of the plasmid were performed using Qiagen Giga Endotoxin-Free kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The control plasmid (pDNA-control) was constructed from the pDNA-IL-10 F129S plasmid by enzymatic excision of the IL-10 gene and insertion of a poly-A sequence thereby keeping all other elements of the backbone identical. All purified plasmids were suspended in a vehicle of 0.2 micron filtered, 3% sucrose solution in Dulbecco's phosphate-buffered saline (0.1 mM pore-filtered, pH 7.2; Gibco, Grand Island, NY, USA) and stored at À20 1C until thawed on ice before injection. Final concentration of the plasmid solution was measured by optical density.
IL-10-neutralizing antibody and IgG control antibody
Lyophilized bulk ion-exchange-purified sheep anti-rat IL-10 (anti-IL-10) IgG-neutralizing antibody as well as non-specific IgG control antibody (National Institute for Biological Standards and Control, Potters Bar, UK) were reconstituted to a concentration of 1.0 mg ml À1 , aliquoted and stored at À20 1C. Aliquots were slowly thawed on ice immediately before injection and diluted with Dulbecco's phosphate-buffered saline to an injection concentration of 0.2 mg in 20 ml. Anti-IL-10 or control IgG were injected i.t., as described.
Oligodeoxynucleotides
Synthetic stimulatory K-type oligodeoxynucleotides were provided by Dennis Klinman at the National Cancer Institute (Frederick, MD, USA). A mix of oligodeoxynucleotides containing the stimulatory sequences, TCGTA and TCGA, were administered. Stock oligodeoxynucleotides were diluted in 20 ml phosphatebuffered saline (PBS) just before i.t. injection.
Glycoprotein120
Glycoprotein120 is a coat protein of the Human Immunodeficiency Virus that is a potent inflammatory agent, inducing the production of inflammatory cytokines from a variety of immune cells. gp120 was injected i.t. at a dose of 3 mg (courtesy of Amgen, Thousand Oaks, CA, USA).
IL-10 protein
Recombinant human IL-10 Fc chimera was purchased from Sigma (St Louis, MO, USA). This construct is a human IL-10 chimera fused to IgG1 that has been mutated to prevent cytotoxicity. The Fc fusion extends the half-life of IL-10 allowing for prolonged activity.
CSF collection
Lumbar CSF was collected using a similar protocol to that described for i.t. injections. Under isoflurane anesthesia, an 18-G needle was inserted between L5 and L6 vertebrae for use as a guide cannula. PE-10 tubing was inserted into this guide and threaded rostrally to the lumbosacral enlargement, as described for i.t. injections. A 3-cc syringe with attached 30-G needle was connected to the free end of the PE-10 tubing and CSF gently withdrawn into the catheter and syringe. Approximately 100 ml of CSF was obtained from each rat and placed into an eppendorf tube on water ice for subsequent immunohistochemistry analysis or frozen in liquid nitrogen for subsequent PCR analysis.
Immunohistochemistry on CSF samples
Cerebrospinal fluid samples were gently inverted to ensure a homogeneous suspension and then 40 ml drops from each sample were plated onto glass coverslips (Fisher Scientific, www.fishersci.com, 12 mm circular No.1) in the wells of a 24-well plate (Corning Inc, Corning, NY, USA) immediately after collection. Cells within CSF were allowed to adhere to the coverslips for 40 min in an incubator (37 1C, 5% CO 2 ). After incubation, immunohistochemical staining for cell phenotype markers was conducted according to standard procedures. All liquids used during the procedure were introduced to and removed from the wells using a pipette at a volume of 500 ml per well. Samples were initially washed twice with PBS, then fixed with 4% paraformaldehyde for 30 min and washed thrice with PBS. Samples were permeabilized and cleared with a 5% H 2 O 2 solution in PBS for 15 min, followed again by three PBS washes.
Overnight incubation in primary detection antibody was done in an incubation buffer containing 5% normal goat serum, 0.1% Triton-X and 0.1% sodium azide in PBS at 4 1C on an agitator. Primary antibody specifications are as follows: ED1 (marker of classic macrophage
Harnessing innate immunity to enhance gene therapy E Sloane et al activation; AbD Serotec, Raleigh, NC, USA; 1:200 dilution for final concentration of 2.5 mg ml À1 ), ED2 (marker of alternative macrophage activation; AbD Serotec; 1:200 dilution for final concentration of 2.5 mg ml À1 ), CD63 (marker of undifferentiated monocytes and mast cells; AbD Serotec; 1:200 dilution for final concentration of 2.5 mg ml À1 ). Primary antibody was removed with three PBS washes followed by incubation in fluorescenceconjugated secondary antibody (Alexa Fluor 594; Invitrogen; Eugene, OR, USA; 1:200 dilution for final concentration of 10 mg ml À1 ) for 2 h at room temperature. Unbound secondary antibody was removed with a final three washes with PBS. After the immunohistochemistry procedure, glass coverslips were mounted onto slides in Vectashield fluorescence mounting medium containing the nuclear stain DAPI (4',6-diamidino-2-phenylindole) (Vector Laboratories Inc, Burlingame, CA, USA). Samples were analyzed using a fluorescence microscope (Olympus BX61, Melville, NY, USA) to capture multiple channel images (Olympus DP70 3.0 camera; Microsuite Biological Suite 2.6 software) to allow for analysis of cell density and phenotypes. Cell counts were conducted by hand using NIH ImageJ 1.37v (NIH, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/) image analysis software, and reflect data collected from eight images per group. Phenotypes were also counted by hand from four images per marker per group, and the percentage of positively labeled cells co-localizing with DAPI to the total DAPI count was calculated.
Reverse transcriptase PCR on CSF samples
Cerebrospinal fluid was collected as described, immediately frozen in liquid nitrogen and stored at À80 1C before processing. cDNA was synthesized using a Cells-Direct III cDNA synthesis kit (Invitrogen) according to manufacturer's instructions. Briefly, CSF samples were centrifuged (1000 g for 10 min at 4 1C), the supernatant was removed and the pellet was washed with 100 ml icecold Dulbecco's phosphate-buffered saline, and recentrifuged (1000 g for 10 min at room temperature) to pellet the cells within the sample and re-suspended in 11 ml lysis buffer and lysis solution for 10 min on ice. 10 ul of cell lysate was added to 1 ul RNAse inhibitor and incubated at 75 1C for 10 min. First-strand cDNA was synthesized by adding 2 ml oligo (Dt), 1 ml dNTP and 7.8 ml nuclease-free water to the cell lysate and incubating at 70 1C for 5 min. After 2 min on ice, 6 ml 5 Â RT buffer, 1 ml RNAse inhibitor, 1 ml Superscript III and 1 ml dithiothreitol were added to the cell lysate and incubated at 50 1C for 50 min and for 5 min at 85 1C. Finally, 1 ml RNase H was added and incubated at 37 1C for 20 min. All cDNA was stored at À80 1C until reverse transcriptase PCR was performed. Exogenous (plasmid derived) IL-10 gene expression was distinguished from endogenous IL-10 by using a forward primer that crosses an exon/intron boundary within the IL-10 sequence and a reverse primer that crosses the boundary between an IL-10 exon and a unique plasmid sequence that forms the 3 0 -UTR. The primer sequences used are as follows: Forward: ACGCTGTCATCGATTTCT; Reverse: CCGCTA GCTCAATTTTTCA.
Data analysis
All statistical comparisons were computed using Statview 5.0.1 (SAS Institute, Cary, NC, USA, www.jmp.com) for the Macintosh. Data from the von Frey test were analyzed as the interpolated 50% threshold (absolute threshold) in log base 10 of stimulus intensity (monofilament stiffness in milligrams Â 10). Behavioral tests of allodynia were analyzed by repeated measures ANOVA (analysis of variance) followed by Fisher's protected least significant difference post hoc comparisons, where appropriate. Immunohistochemistry data, including cell counts from CSF, were analyzed by one-way ANOVA followed by post hoc comparisons, where appropriate.
